Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
According to the company's disclosures, the platform may provide access to FDA-approved semaglutide and tirzepatide medications manufactured by major pharmaceutical companies, depending on clinician evaluation and patient eligibility
GLP-1s in general are typically recommended and usually only covered by insurance for people with obesity (defined as a BMI greater than 30) as well as those with a BMI greater than 27 and one or more weight-related conditions such as high blood pressure, type 2 diabetes, or high cholesterol
Food and Drug Administration (FDA) Consumer Updates on Dual GIP/GLP-1 Receptor Agonist Efficacy, Approved Tirzepatide Clinical Guidance, and Public Safety Alerts (USA Gov)
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO [see Adverse Reactions (6)]
US$ 23.78
US$ 26.42
US$ 26.94
US$ 22.47
US$ 23.82
